Effectiveness and Safety of Dexmedetomidine in Neonates With Hypoxic Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

Overview

Journal J Pediatr Pharmacol Ther

Specialty Pediatrics

Date 2024 Jun 12

PMID 38863848

Authors

Ceyda Acun

Mahmoud Ali

Wei Liu

Sreenivas Karnati

Kelsey Fink

Hany Aly

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of this study was to evaluate and compare the effectiveness and safety of dexmedetomidine as monotherapy between neonates with mild hypoxic ischemic encephalopathy (HIE) and moderate to severe HIE treated with therapeutic hypothermia (TH).

Methods: This retrospective study included neonates of gestational age ≥36 weeks with a diagnosis of HIE and undergoing TH between January 2014 and December 2021. Patients were included if they received at least 6 hours of continuous sedation with dexmedetomidine. Baseline characteristics, dose and duration of medication, adverse events, liver and kidney function tests, and hospital course were reviewed.

Results: Of the 97 neonates included, 46 had mild, 42 had moderate, and 9 had severe HIE. Dexmedetomidine was initiated at a median 5 hours of life, and the median infusion duration was 77 (46-87) hours. Fifty-two (53.6%) required at least 1 breakthrough opioid or sedative during the first 24 hours of dexmedetomidine infusion. Overall, 40 patients (41.2%) had at least 1 bradycardia episode with heart rate <80 beats/min and 14 patients (14.4%) had heart rate <70 beats/min. Hypotension was experienced by 7 patients (7.2%). Fifty-two patients (53.6%) were intubated in the delivery room and 33/52 (63.5%) were extubated on day of life 1 during dexmedetomidine infusion.

Conclusions: Dexmedetomidine as monotherapy was effective and safe sedation for infants with HIE undergoing hypothermia. The most common side effect of dexmedetomidine was bradycardia. -Dexmedetomidine may be considered as first and single agent for neonates with HIE undergoing TH.

Citing Articles

Sedation and Pain Management in Neonates Undergoing Therapeutic Hypothermia for Hypoxic-Ischemic Encephalopathy.

Kokhanov A, Chen P Children (Basel). 2025; 12(2).

PMID: 40003355 PMC: 11854431. DOI: 10.3390/children12020253.

Study on the sedative effect and safety of oral midazolam combined with dexmedetomidine nasal drops in children during magnetic resonance imaging examination.

Li Y, Lei R Front Pediatr. 2025; 12():1500277.

PMID: 39834495 PMC: 11743695. DOI: 10.3389/fped.2024.1500277.

Progress on the Mechanisms and Neuroprotective Benefits of Dexmedetomidine in Brain Diseases.

Tao Z, Li P, Zhao X Brain Behav. 2024; 14(11):e70116.

PMID: 39482839 PMC: 11527817. DOI: 10.1002/brb3.70116.

References

Natarajan G, Hamrick S, Zaniletti I, Lee K, Mietzsch U, DiGeronimo R . Opioid exposure during therapeutic hypothermia and short-term outcomes in neonatal encephalopathy. J Perinatol. 2022; 42(8):1017-1025. DOI: 10.1038/s41372-022-01400-x. View

Alburaki W, Scringer-Wilkes M, Dawoud F, Oliver N, Lind J, Zein H . Feeding during therapeutic hypothermia is safe and may improve outcomes in newborns with perinatal asphyxia. J Matern Fetal Neonatal Med. 2022; 35(25):9440-9444. DOI: 10.1080/14767058.2022.2041594. View

Chrysostomou C, Schulman S, Herrera Castellanos M, Cofer B, Mitra S, da Rocha M . A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. J Pediatr. 2013; 164(2):276-82.e1-3. DOI: 10.1016/j.jpeds.2013.10.002. View

Tobias J . Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology. Pediatr Crit Care Med. 2007; 8(2):115-31. DOI: 10.1097/01.PCC.0000257100.31779.41. View

Chay P, DUFFY B, Walker J . Pharmacokinetic-pharmacodynamic relationships of morphine in neonates. Clin Pharmacol Ther. 1992; 51(3):334-42. DOI: 10.1038/clpt.1992.30. View

Angeles D, Wycliffe N, Michelson D, Holshouser B, Deming D, Pearce W . Use of opioids in asphyxiated term neonates: effects on neuroimaging and clinical outcome. Pediatr Res. 2005; 57(6):873-8. DOI: 10.1203/01.PDR.0000157676.45088.8C. View

OMara K, Weiss M . Dexmedetomidine for Sedation of Neonates with HIE Undergoing Therapeutic Hypothermia: A Single-Center Experience. AJP Rep. 2018; 8(3):e168-e173. PMC: 6123058. DOI: 10.1055/s-0038-1669938. View

Davidson J, Fraser M, Naylor A, Roelfsema V, Gunn A, Bennet L . Effect of cerebral hypothermia on cortisol and adrenocorticotropic hormone responses after umbilical cord occlusion in preterm fetal sheep. Pediatr Res. 2007; 63(1):51-5. DOI: 10.1203/PDR.0b013e31815b8eb4. View

Sarnat H, Sarnat M . Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. Arch Neurol. 1976; 33(10):696-705. DOI: 10.1001/archneur.1976.00500100030012. View

10.

Sellas M, Kyllonen K, Lepak M, Rodriguez R . Dexmedetomidine for the Management of Postoperative Pain and Sedation in Newborns. J Pediatr Pharmacol Ther. 2019; 24(3):227-233. PMC: 6510519. DOI: 10.5863/1551-6776-24.3.227. View

11.

Natarajan G, Shankaran S, Laptook A, McDonald S, Pappas A, Hintz S . Association between sedation-analgesia and neurodevelopment outcomes in neonatal hypoxic-ischemic encephalopathy. J Perinatol. 2018; 38(8):1060-1067. PMC: 6092226. DOI: 10.1038/s41372-018-0126-7. View

12.

Dean J, George S, Naylor A, Mallard C, Gunn A, Bennet L . Partial neuroprotection with low-dose infusion of the alpha2-adrenergic receptor agonist clonidine after severe hypoxia in preterm fetal sheep. Neuropharmacology. 2008; 55(2):166-74. DOI: 10.1016/j.neuropharm.2008.05.009. View

13.

Hummel P, Puchalski M, Creech S, Weiss M . Clinical reliability and validity of the N-PASS: neonatal pain, agitation and sedation scale with prolonged pain. J Perinatol. 2008; 28(1):55-60. DOI: 10.1038/sj.jp.7211861. View

14.

Liu L, Johnson H, Cousens S, Perin J, Scott S, Lawn J . Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012; 379(9832):2151-61. DOI: 10.1016/S0140-6736(12)60560-1. View

15.

Lewis S, Nicholson A, Smith A, Alderson P . Alpha-2 adrenergic agonists for the prevention of shivering following general anaesthesia. Cochrane Database Syst Rev. 2015; (8):CD011107. PMC: 9221859. DOI: 10.1002/14651858.CD011107.pub2. View

16.

Reiter P, Pietras M, Dobyns E . Prolonged dexmedetomidine infusions in critically ill infants and children. Indian Pediatr. 2009; 46(9):767-73. View

17.

Shipley L, Gale C, Sharkey D . Trends in the incidence and management of hypoxic-ischaemic encephalopathy in the therapeutic hypothermia era: a national population study. Arch Dis Child Fetal Neonatal Ed. 2021; 106(5):529-534. DOI: 10.1136/archdischild-2020-320902. View

18.

OMara K, Gal P, Wimmer J, Ransom J, Carlos R, Dimaguila M . Dexmedetomidine versus standard therapy with fentanyl for sedation in mechanically ventilated premature neonates. J Pediatr Pharmacol Ther. 2012; 17(3):252-62. PMC: 3526929. DOI: 10.5863/1551-6776-17.3.252. View

19.

Frymoyer A, Bonifacio S, Drover D, Su F, Wustoff C, Van Meurs K . Decreased Morphine Clearance in Neonates With Hypoxic Ischemic Encephalopathy Receiving Hypothermia. J Clin Pharmacol. 2016; 57(1):64-76. PMC: 5240044. DOI: 10.1002/jcph.775. View

20.

Thoresen M, Satas S, Loberg E, Whitelaw A, Acolet D, Lindgren C . Twenty-four hours of mild hypothermia in unsedated newborn pigs starting after a severe global hypoxic-ischemic insult is not neuroprotective. Pediatr Res. 2001; 50(3):405-11. DOI: 10.1203/00006450-200109000-00017. View